ProShare Advisors
RYTM icon

ProShare Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

ProShare Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
9,476
-1,244
-12% -$112K ﹤0.01% 788
2026
Q1 		$932K Sell
10,720
-1,902
-15% -$185K ﹤0.01% 813
2025
Q4 		$1.35M Buy
12,622
+1,323
+12% +$140K ﹤0.01% 752
2025
Q3 		$1.14M Sell
11,299
-2,237
-17% -$208K ﹤0.01% 773
2025
Q2 		$855K Sell
13,536
-1,168
-8% -$71.5K ﹤0.01% 874
2025
Q1 		$779K Sell
14,704
-3,624
-20% -$201K ﹤0.01% 894
2024
Q4 		$1.03M Buy
18,328
+4,370
+31% +$241K ﹤0.01% 900
2024
Q3 		$731K Buy
13,958
+3,042
+28% +$146K ﹤0.01% 922
2024
Q2 		$448K Sell
10,916
-2,892
-21% -$115K ﹤0.01% 1039
2024
Q1 		$598K Buy
13,808
+1,527
+12% +$66.8K ﹤0.01% 982
2023
Q4 		$565K Buy
12,281
+1,886
+18% +$59.5K ﹤0.01% 970
2023
Q3 		$238K Buy
10,395
+34
+0.3% +$761 ﹤0.01% 1356
2023
Q2 		$171K Buy
+10,361
New +$187K ﹤0.01% 1573
2022
Q2 		– Sell
-13,465
Closed -$155K – 2070
2022
Q1 		$155K Sell
13,465
-3,242
-19% -$28.5K ﹤0.01% 1947
2021
Q4 		$168K Buy
16,707
+332
+2% +$3.73K ﹤0.01% 2089
2021
Q3 		$214K Sell
16,375
-4,075
-20% -$62.2K ﹤0.01% 1756
2021
Q2 		$400K Buy
20,450
+3,454
+20% +$71.7K ﹤0.01% 1696
2021
Q1 		$362K Buy
16,996
+2,727
+19% +$79.1K ﹤0.01% 1683
2020
Q4 		$424K Buy
14,269
+3,040
+27% +$77.3K ﹤0.01% 1375
2020
Q3 		$243K Sell
11,229
-383
-3% -$8.78K ﹤0.01% 1312
2020
Q2 		$259K Buy
+11,612
New +$226K ﹤0.01% 1308
2020
Q1 		– Sell
-13,472
Closed -$309K – 1506
2019
Q4 		$309K Buy
13,472
+1,514
+13% +$33.6K ﹤0.01% 1326
2019
Q3 		$258K Buy
11,958
+297
+3% +$6.37K ﹤0.01% 1305
2019
Q2 		$257K Sell
11,661
-1,682
-13% -$42.5K ﹤0.01% 1320
2019
Q1 		$366K Buy
13,343
+77
+0.6% +$2.21K ﹤0.01% 1160
2018
Q4 		$357K Buy
+13,266
New +$367K ﹤0.01% 1066

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ProShare Advisors's RYTM Position: Q2 2026 in Review

ProShare Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 12% in Q2 2026, selling an estimated $112K and leaving 9,476 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #788.

ProShare Advisors first reported a position in RYTM in Q4 2018 and has held it in 26 quarters since. The position peaked at $1.35M in Q4 2025. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • ProShare Advisors held 9,476 shares of Rhythm Pharmaceuticals worth $1.05M as of Q2 2026.
  • ProShare Advisors sold 1,244 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $112K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #788 holding.
  • ProShare Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • ProShare Advisors's Rhythm Pharmaceuticals position peaked at $1.35M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.